Have you ever wondered what it’s like to be a medical oncologist? Follow our Dr. Eric Singhi throughout his day.
Eric K. Singhi, M.D.
Department of General Oncology, Division of Cancer Medicine
Meet Eric Singhi, M.D.
3 common myths about lung cancer
A day in the life of a medical oncologist with Dr. Eric Singhi
Featured Articles
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | Medical University of South Carolina, Charleston, South Carolina, US, MD |
| 2012 | Duke University, Durham, North Carolina, US, BS in Bachelor of Science in Neuroscience |
Postgraduate Training
| 2019-2022 | Clinical Fellowship, Hematology/Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Clinical Residency, Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee |
Board Certifications
| 2022 | American Board of Internal Medicine - Hematology |
| 2022 | American Board of Internal Medicine - Medical Oncology |
| 2019 | American Board of Internal Medicine |
Experience & Service
Institutional Committee Activities
Patient Safety Quality Officer, Patient Safety Quality Officer of Thoracic Oncology Service Line, 2024 - Present
Member, Thoracic/Head and Neck Medical Oncology Representative for Clinical Effectiveness Advisory Committee, 2024 - Present
Ambassador, MD Anderson Community Ambassador for Lung Cancer, 2024 - Present
Faculty Member, Thoracic Service Line Physician Leadership, 2023 - Present
Physician Lead, Research Program/ Community Outreach & Engagement Physician Lead, 2023 - Present
Co-Chair, General Oncology Grand Rounds, 2023 - Present
Co-Chair, Co-Chair, Thoracic/Head and Neck Medical Oncology Journal Club, 2023 - Present
Faculty Member, Faculty Member, Clinical Competency Committee for Hematology/Medical Oncology Fellowship Program, 2023 - Present
Co-Director, Co-Director, Thoracic Medical Oncology Rotation for Hematology/Medical Oncology Fellowship Program, 2023 - Present
Faculty Member, Lung Cancer Center Support Grant (CCSG) Program, 2003 - Present
Honors & Awards
| 2024 | International Association for Study of Lung Cancer (IASLC) Academy Awardee, International Association for Study of Lung Cancer (IASLC) |
| 2023 | Junior Faculty Travel Award, Hawaii Global Summit on Thoracic Malignancies |
| 2023 | MD Anderson Awesome Job Award, The University of Texas MD Anderson Cancer Center |
| 2023 | Medical Spotlight Keynote Speaker Award, MedNews Week International |
| 2023 | Patient Education Ambassador, Global Resource for Advancing Cancer Education |
| 2022 | 2022 Young Investigator Award, EGFR Resisters Research Summit |
| 2022 | MD Anderson Awesome Job Award, MD Anderson Cancer Center |
| 2021 | Patient Education Ambassador, Global Resource for Advancing Cancer Education |
| 2021 | Physician Educators Certificate Program (PECP), University of Texas Health Houston |
| 2016 | Alpha Omega Alpha Honor Medical Society, Medical University of South Carolina |
| 2016 | Gold Humanism Honor Society, Medical University of South Carolina |
| 2015 | Rich Merit Scholarship, Medical University of South Carolina |
| 2014 | Jean Wilson Endowed Merit Scholarship, Medical University of South Carolina |
| 2013 | Caroline B. Lown Merit Scholarship, Medical University of South Carolina |
| 2012 | Graduation with Distinction, Duke University |
| 2012 | Magna Cum Laude, Duke University |
| 2012 | Phi Beta Kappa, Duke University |
Selected Publications
Peer-Reviewed Articles
- Sridhar A, West HJ, Singhi EK. Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer 25(7):e286-e294, 2024. e-Pub 2024. PMID: 38772808.
- Mysore M, Singhi D, Singhi EK. Caring for Your Heart During Cancer Treatment. JAMA Oncol 10(10):1447, 2024. e-Pub 2024. PMID: 39207763.
- Abu Rous F, Desai A, Singhi EK. Clinical Trials for Patients With Cancer. JAMA Oncol 10(3):416, 2024. e-Pub 2024. PMID: 38270965.
- Sridhar A, West H, Singhi EK. rief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2024.
- Kareff SA, Sridhar A, Dhawan N, Anampa-Guzman A, Singhi EK, Velazquez AI. The Democratization of Hematology-Oncology Medical Education during the COVID-19 Pandemic. Cancer Invest 41(6):548-558, 2023. e-Pub 2023. PMID: 37357925.
- Singhi EK, Mott F, Worse M, Leung CH, Lee JJ, Carter B, Presley CJ, Heymach JV, Altan M. Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer. Oncol Lett 25(6):262, 2023. e-Pub 2023. PMID: 37216156.
- Kareff SA, Sridhar A, Dhawan N, Anampa-Guzman A, Singhi EK, Velazquez AI. The democratization of hematology-oncology medical education during the COVID-19 pandemic. Cancer Investigation 0:1-9, 2023. e-Pub 2023.
- Singhi EK, Feldman J, West HJ. The Multidisciplinary Cancer Conference. JAMA Oncol 9(2):288, 2023. e-Pub 2022. PMID: 36547939.
- Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A. Lung Cancer Treatment Advances in 2022. Cancer Invest 41(1):1-20, 2023. e-Pub 2022. PMID: 36036470.
- Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer 23(3):236-243, 2022. e-Pub 2022. PMID: 35216923.
- Hu Z, Singhi EK, Apostolidou E, Mai B, Juneja HS, Hu S. Mass-forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia. Int J Lab Hematol 43(3):e135-e137, 2021. e-Pub 2021. PMID: 33314782.
- Singhi EK, Mott F, Worst M, Borg M, Johnson D, Lewis J, etal. Clinical outcomes of immunotherapy continued beyond radiographic progression in older adults with advanced non-small cell lung cancer. Journal for Immunotherapy of Cancer, 2021. e-Pub 2021.
- Singhi EK, Dupuis MM, Ross JA, Rieber AG, Bhadkamkar NA. Medical Hematology/Oncology Fellows' Perceptions of Online Medical Education During the COVID-19 Pandemic. J Cancer Educ 35(5):1034-1040, 2020. e-Pub 2020. PMID: 32888144.
- Feld E, Singhi EK, Phillips S, Huang LC, Shyr Y, Horn L. Palliative Care Referrals for Advanced Non-small-cell Lung Cancer (NSCLC): Patient and Provider Attitudes and Practices. Clin Lung Cancer 20(3):e291-e298, 2019. e-Pub 2019. PMID: 30862422.
- Singhi EK, Moore DC, Muslimani A. Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies. P T 43(7):410-429, 2018. e-Pub 2018. PMID: 30013298.
- Patel K, Patel M, Gor A, Naidu S, Nathwani N, Kothadia R, Parekh S, Singhi EK. Oncology practice transformation helps deliver patient-centered cancer care in a community oncology practice. The American Journal of Managed Care, 2018. e-Pub 2018.
- Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, etal. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension, 2017. e-Pub 2017.
- Singhi EK, Pommerenke AW, Mushtaq S, Cummings KM, etal. Addressing tobacco use at NCI designated cancer centers: Online resources available for patients. Journal of Clinical Oncology, 2015. e-Pub 2015.
- Nikolova YS, Singhi EK, Drabant EM, Hariri AR. Reward-related ventral striatum reactivity mediates gender-specific effects of a galanin remote enhancer haplotype on problem drinking. Genes Brain Behav 12(5):516-24, 2013. e-Pub 2013. PMID: 23489876.
- Singhi EK, Dupuis MM, Ross JA, Rieber AG, Bhadkamkar NA. Medical Hematology/Oncology Fellows' Perceptions of Online Medical Education During the COVID-19 Pandemic. J Cancer Educ. PMID: 32888144.
Invited Articles
- Singhi EK, Halmos B. Deciding Between Frontline Regimens in Advanced-Stage, EGFR-Mutant NSCLC: Is There a Place for More Intense Combinations Vs Osimertinib in the Treatment Landscape?, 2024.
- Singhi EK, West HJ. Rethinking the treatment approach to resectable non-small cell lung cancer: do new approvals always translate to clinical value. ASCO Daily News, 2023. e-Pub 2023.
- Mushtaq S, Singhi EK, Stuart R. Triple-triple hit lymphoma. Case Reports in Internal Medicine, 2015. e-Pub 2015.
Other Articles
- Singhi EK, West HJ When Practice Evolves Faster Than the Data in Early-Stage Non–Small Cell Lung Cancer. ASCO Daily News, 2022.
- Singhi EK, Gay CM Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer. Transl Lung Cancer Res 9(5):2051-2058, 2020. PMID: 33209625.
- Singhi EK, Horn L, Sequist LV, Heymach J, Langer CJ Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Am Soc Clin Oncol Educ Book 39:e187-e197, 2019. PMID: 31099642.
- Singhi EK, Li BC, Denny JC Simmering Below the Surface: Sweet's Syndrome with Multiple Myeloma. Am J Med 131(9):1058-1060, 2018. PMID: 29729238.
- Singhi EK, Horn L Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer. Future Oncol 14(18):1781-1787, 2018. PMID: 29506392.
- Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension 71(2):e1-e8, 2018. PMID: 29279311.
Editorials
- Singhi EK. Disseminated Intravascular Coagulation (DIC). Vanderbilt University Medical Center Commodore Compendium, 2019.
Books (edited and written)
- Abu Rous, F, Desai, A, Singhi, EK. Clinical Trials for Patients With Cancer, 2024.
Selected Presentations & Talks
National Presentations
- 2024. “Basics” of Lung Cancer for the Community. Invited. Houston, Texas, US.
- 2024. Early-Career Round Table Session. Invited. Santa Monica, California, US.
- 2023. Tailoring the treatment approach to resectable stage non-small cell lung cancer. Invited. Binaytara Foundation 2023 Updates on Hematology and Oncology. Houston, Texas, US.
Formal Peers
- 2024. Navigating Social Media: Overview for the Online Oncologist. Houston, Texas, US.
- 2024. Tailoring the treatment approach to resectable non small cell lung cancer BTF's 2023 Updates on Hematology & Oncology. Houston, Texas, US.
- 2024. Management of Metastatic Non Small Cell Lung Cancer without Driver Alterations. Houston, Texas, US.
- 2024. Management of Metastatic Non Small Cell Lung Cancer with Driver Alterations. Houston, Texas, US.
- 2024. Lung Cancer Board Review Lecture. Houston, Texas, US.
- 2024. Treatment of Early-Stage and Locally Advanced NSCLC: A Chalk Talk for Oncology Fellows. Houston, Texas, US.
- 2024. MD Anderson Fellowship Journal Club Discussion: Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases Expert Medical Oncology Discussant. Houston, Texas, US.
- 2024. Lung Cancer Comprehensive Care Overview Nurses and Allied Healthcare Professionals Didactic Series. Houston, Texas, US.
- 2024. Treatment of Stage I to III NSCLC: Fellowship Didactic Talk. Houston, Texas, US.
- 2024. Immunotherapy in the management of patients with metastatic non-small cell lung cancer. Houston, Texas, US.
- 2023. Navigating Social Media: A Guide for the Online Oncologist. Invited. Navigating Social Media: A Guide for the Online Oncologist. Houston, TX, US.
- 2023. Tailoring the treatment approach to resectable non small cell lung cancer. Invited. Tailoring the treatment approach to resectable non small cell lung cancer. Houston, TX, US.
- 2023. Navigating Social Media as an Oncologist. Invited. Navigating Social Media as an Oncologist. Houston, TX, US.
Grant & Contract Support
| Date: | 2024 - 2025 |
| Title: | “Investigating Clinical Outcomes in Young Adults with Non-Small Cell Lung Cancer,” Rexanna's Foundation for Fighting Lung Cancer |
| Funding Source: | Victor Elias Research Grant Funded Project |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | A Pilot study to assess the Concordance Between MyBreathPrint Device results and Tissue Biopsy in patients with suspected lung cancer: Single center, single arm, prospective, observational design |
| Funding Source: | N/A |
| Role: | Co-PI |
Patient Reviews
CV information above last modified March 19, 2025